Enanta Pharma to Participate at Leerink Partners Global Biopharma Conference
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter
Enanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Conference
Enanta to Provide Updates on its Research and Development Programs
Enanta Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Enanta Pharmaceuticals to Participate at Evercore ISI HealthCONx Conference
While a COVID-19 patent battle with Pfizer rumbles on, Enanta Pharmaceuticals has hit pause on development of a dual inhibitor for human metapneumovirus and respiratory syncytial virus (RSV) in an effort to pave a cash runway into 2027.
Enanta Pharmaceuticals to Host Conference Call
Enanta Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss Advances in the Treatment Landscape for Respiratory Syncytial Virus (RSV) and its Proprietary RSV Pipeline
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced that data for EDP-323, its oral, once-daily, L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at the 9th European Scientific Working Group on Influenza (ESWI) Influenza Conference on September 17-20, 2023 at the Palacio de Congresos de Valencia in Valencia, Spain.